Novo Nordisk opens new research centre in Seattle
Novo Nordisk announced the official opening of the company’s new inflammation research centre based in Seattle. The research centre will leverage Novo Nordisk’s strong knowledge within the field of proteins, in order to further build the company’s clinical pipeline of products for the treatment of chronic inflammatory diseases. Novo Nordisk currently has four projects in early clinical development within the field of inflammation in rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus.
“Seattle is a biotech centre of excellence, and placing our inflammation research centre here allows us to attract top scientists and collaborate with high quality partners,” said Mads Krogsgaard Thomsen, Novo Nordisk’s chief science officer. “By investing in early stage research we hope to find the underlying causes for different inflammatory conditions and develop new treatments for these diseases.”
Novo Nordisk announced its plans to create a new research centre in Seattle in August 2008 and has assembled a highly skilled management team led by Don Foster, vice president of inflammation. It is planned that the centre will have a total of 60 employees by the end of 2010. Research activities in Seattle will complement continuing biopharmaceutical research activities in Novo Nordisk’s research sites in Måløv in Denmark and Beijing in China.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Heart disease specialists meet Spanish footballers to develop tools for detecting sudden death syndrome - Applied Biosystems hosts first symposium on sudden death in football players and other European athletes
Balzan Prizes 2010: 1 Million Francs to stem cell researcher
S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission for the Treatment of Myelofibrosis
